These findings suggest that targeting the ERRγ/GBP5 axis may be a promising therapeutic strategy for MI, and DY131 could serve as a potential novel therapeutic agent for ischemic cardiomyopathy. Here, GBP5 is linked to ischemic cardiomyopathy.